Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine

Vaccine

Volumn 25, Issue 16 SPEC. ISS., 2007, Pages 3179-3191

  McMurry, Julie A ^a   Gregory, Stephen H ^b   Moise, Leonard ^a,b   Rivera, Daniel ^a,b   Buus, Soren ^c   De Groot, Anne S ^a,b  

^a EpiVax Inc   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Epitope; Francisella tularensis; HLA class II; Immunoinformatics; T cell; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; EPITOPE; SCHU4 ANTIGEN; T LYMPHOCYTE ANTIGEN; TULAREMIA VACCINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; FEMALE; FRANCISELLA TULARENSIS; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; MALE; MICROBIAL DIVERSITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE; TULAREMIA; UNINDEXED SEQUENCE;

EID: 33947580575     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.039     Document Type: Article

References (32)

1. Dennis D.T., Inglesby T.V., Henderson D.A., et al. Tularemia as a biological weapon: medical and public health management. JAMA 285 June (21) (2001) 2763-2773 [Review]
2. Larsson P., Oyston P.C., Chain P., et al. The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet 37 February (2) (2005) 153-159
3. Katz J.M., Lu X., Galphin J.C., and Clements J.D. Heat-labile enterotoxin from Escherichia coli as an adjuvant for oral influenza vaccination. In: Brown L.E., Hampson A.W., and Webster R.G. (Eds). Options for the Control of Influenza III (1996), Elsevier, New York 292-297
4. Tarnvik A. Nature of protective immunity to Francisella tularensis. Rev Infect Dis 11 May-June (3) (1989) 440-451 [Review]
5. Fulop M., Mastroeni P., Green M., and Titball R.W. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19 August (31) (2001) 4465-4472
6. Yee D., Rhinehart-Jones T.R., and Elkins K.L. Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellularpathogen, Francisella tularensis strain LVS. J Immunol 157 December (11) (1996) 5042-5048
7. Conlan J.W., Sjostedt A., and North R.J. CD4+ and CD8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect Immun 62 December (12) (1994) 5603-5607
8. Duckett N.S., Olmos S., Durrant D.M., and Metzger D.W. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect Immun 73 April (4) (2005) 2306-2311
9. Rhinehart-Jones T.R., Fortier A.H., and Elkins K.L. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun 62 August (8) (1994) 3129-3137
10. Tarnvik A., Ericsson M., Golovliov I., Sandstrom G., and Sjostedt A. Orchestration of the protective immune response to intracellular bacteria: Francisella tularensis as a model organism. FEMS Immunol Med Microbiol 13 March (3) (1996) 221-255
11. Golovliov I., Ericsson M., Akerblom L., Sandstrom G., Tarnvik A., and Sjostedt A. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis. Vaccine 13 February (3) (1995) 261-267
12. Gomez M., Johnson S., and Gennaro M.L. Identification of Mycobacterium tuberculosis secreted proteins by a bioinformatic approach. Infect Immunol 68 4 (2000) 2323-2327
13. McMurry J., Sbai H., Gennaro M.L., Carter E.J., Martin W., and De Groot A.S. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinb) 85 January-March (1-2) (2005) 95-105
14. Kall L., Krogh A., and Sonnhammer E.L. A combined transmembrane topology and signal peptide prediction method. J Mol Biol 338 May (5) (2004) 1027-1036
15. Juncker A.S., Willenbrock H., Von Heijne G., Brunak S., Nielsen H., and Krogh A. Prediction of lipoprotein signal peptides in Gram-negative bacteria. Protein Sci 12 August (8) (2003) 1652-1662
16. De Groot A.S., Bosma A., Chinai N., et al. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 19 31 (2001) 4385-4395
17. Sturniolo T., Bono E., Ding J., et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17 6 (1999) 555-561
18. Southwood S., Sidney J., Kondo A., et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160 April (7) (1998) 3363-3373
19. De Groot A.S., Rayner J., and Martin W. Modeling the immunogenicity of the therapeutic proteins using T cell epitope mapping. In: Brown F., and Suis A.M. (Eds). Immunogenicity of therapeutic biological products. Developments in biologicals vol. 112 (2003), Karger, Basel 71-80
20. De Groot A.S., and Berzofsky J.A. From genome to vaccine-new immunoinformatics tools for vaccine design. Methods 34 December (4) (2004) 425-428
21. Sette A., and Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50 November (3-4) (1999) 201-212 [Review]
22. Altschul S.F., Gish W., Miller W., Myers E.W., and Lipman D.J. Basic local alignment search tool. J Mol Biol 215 October (3) (1990) 403-410
23. Sylvester-Hvid C., Kristensen N., Blicher T., et al. Establishment of a quantitative ELISA capable of determining peptide-MHC class I interaction. Tissue Antigens 59 April (4) (2002) 251-258
24. Reijonen H., and Kwok W.W. Use of HLA class II tetramers in tracking antigen-specific T cells and mapping T-cell epitopes. Methods 29 March (3) (2003) 282-288 [Review]
25. Teutsch S.M., Martone W.J., Brink E.W., et al. Pneumonic tularemia on Martha's Vineyard. N Engl J Med 301 (1979) 826-828
26. Feldman K.A., Enscore R.E., Lathrop S.L., et al. An outbreak of primary pneumonic tularemia on Martha's Vineyard. N Engl J Med 345 (2001) 1601-1606
27. Lai X.H., Golovliov I., and Sjostedt A. Expression of IglC is necessary for intracellular growth and induction of apoptosis in murine macrophages by Francisella tularensis. Microb Pathog 37 November (5) (2004) 225-230
28. Lazarski C.A., Chaves F.A., Sant A.J., et al. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity 23 July (1) (2005) 29-40
29. Koita O.A., Dabitao D., Mahamadou I., et al. Confirmation of immunogenic consensus sequence HIV-1 T-cell epitopes in Bamako, Mali and Providence. Rhode Island Hum Vaccine 2 May-June (3) (2006) 119-128
30. Oseroff C., Kos F., Bui H.H., et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci USA 102 September (39) (2005) 13980-13985
31. Pasquetto V., Bui H.H., Giannino R., et al. HLA-A*0201, HLA-A*1101 and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J Immunol 175 (2005) 5504-5515
32. De Groot A.S., McMurry J., Marcon L., et al. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 23 March (17-18) (2005) 2121-2131